RxDataLab

Sign In Get Started

Biotech intelligence for BD, strategy, and research teams

What companies do, not what they say. Trial changes, SEC filings, and market data from primary sources.

Get Early Access Login

BioHedge Monitor

Tracking SEC Schedule 13D/G filings from institutional investors in biotech.

Filings through Feb 2, 2026
SEC data updated daily
Weekly summaries with analysis →
Last 60 Days
11
New positions
2 / 9
Increased / Decreased
17 / 8
13D / 13G
9
Funds on 21 companies

Multi-Fund Activity

Companies with two or more institutional investors filing in the same period.

Accumulating
KYMR Kymera Therapeutics, Inc.
+9.9%
2 funds
BVF Partners L.P. (+8.5%) , Baker Brothers Advisors (+1.4%)
IRON Disc Medicine, Inc.
+5.0%
2 funds
RA Capital Management (+5.9%) , Atlas Ventures (-0.9%)
Reducing

None in this period

Filing Volume by Week

13D 13G
G RA Capital Management
Feb 2, 2026
HLXC HELIX ACQUISITION CORP II
7.0%
D BVF Partners L.P.
Jan 30, 2026
RPTX Repare Therapeutics Inc.
0.0% ▼-24.0 67d
D OrbiMed
Jan 27, 2026
CRVS Corvus Pharmaceuticals, Inc.
10.3% ▼-1.9 258d
D Perceptive Advisors
Jan 26, 2026
TRIB TRINITY BIOTECH
9.9% 34d
G Perceptive Advisors
Jan 22, 2026
SABS SAB BIOTHERAPEUTICS INC
7.3%
D Fairmount Funds Management LLC
Jan 22, 2026
COGT Cogent Biosciences, Inc.
9.9% 66d
D Fairmount Funds Management LLC
Jan 22, 2026
APGE Apogee Therapeutics, Inc.
10.0% 100d
D MPM BioImpact
Jan 16, 2026
HOWL Werewolf Therapeutics, Inc.
6.9% ▼-1.3 18d
D Perceptive Advisors
Jan 16, 2026
ATHA athira pharma
20.0% ▼-0.1 24d
G RA Capital Management
Jan 16, 2026
IPSC Century Therapeutics, Inc.
9.9%
D Baker Brothers Advisors
Jan 14, 2026
DBVT DBV Technologies S.A.
10.0% ▼-7.1 289d
D RA Capital Management
Jan 9, 2026
CDTX Cidara Therapeutics, Inc.
0.0% ▼-10.7 53d
G EcoR1 Capital
Jan 9, 2026
MREO MEREO BIOPHARMA GROUP PL-ADR
9.4%
G RA Capital Management
Jan 7, 2026
IRON Disc Medicine, Inc.
5.9%
D Perceptive Advisors
Jan 2, 2026
MGTX MeiraGTx Holdings plc
12.9%
D BIOS Partners
Dec 29, 2025
INAB IN8BIO, INC.
4.0% ▼-6.0 235d
D MPM BioImpact
Dec 29, 2025
HOWL Werewolf Therapeutics, Inc.
8.2% ▼-1.8 26d
D Perceptive Advisors
Dec 23, 2025
ATHA athira pharma
20.1% ▲6.2 1d
D Perceptive Advisors
Dec 23, 2025
TRIB TRINITY BIOTECH
9.9% ▼-12.6 60d
G Perceptive Advisors
Dec 23, 2025
TENX TENAX THERAPEUTICS, INC.
7.0%
D Perceptive Advisors
Dec 22, 2025
ATHA athira pharma
13.9%
D Baker Brothers Advisors
Dec 19, 2025
KOD Kodiak Sciences Inc.
32.8%
D RA Capital Management
Dec 18, 2025
VOR Vor Biopharma Inc.
14.0% ▲4.1 34d
G RA Capital Management
Dec 18, 2025
OVID OVID THERAPEUTICS INC
9.9%
G RA Capital Management
Dec 18, 2025
RZLT REZOLUTE INC
9.9%

This page reflects disclosed ownership changes only. Absence of activity does not imply absence of interest.

Understanding Schedule 13D and 13G Filings

Schedule 13D and 13G filings are SEC disclosures required when an investor acquires more than 5% of a company's outstanding shares.

Schedule 13D (Activist)

Filed when an investor may seek to influence management, board composition, or corporate strategy. Requires disclosure of investment purpose and plans.

Schedule 13G (Passive)

Filed by passive investors (mutual funds, index funds, institutions) with no intent to influence. Simpler filing requirements.

Gap column: Days since previous filing for the same fund+company pair. Short gaps may indicate active accumulation or distribution.

Data source: SEC EDGAR. Filings typically available within 4 hours of submission.

Get Fund Activity for Your Sectors

We build focused data tools for BD, strategy, and research teams. Tell us what sectors or tickers you follow and we'll send you fund activity updates relevant to your coverage.

Get Tailored Alerts or email [email protected]